Everest Medicines (SEHK:1952) Could Be 34% Undervalued Following CARDAMYST Approval

Everest Medicines (SEHK:1952) just crossed a major milestone, with China’s NMPA approving CARDAMYST, the first self administered nasal spray for acute PSVT episodes. The approval is supported by data showing rapid rhythm conversion and fewer emergency visits.

For Everest Medicines, the CARDAMYST approval lands after a choppy stretch in the market, with the share price at HK$27.98 and a 30 day share price return down 19.27%. The 90 day move is up 14.20%, and the 1 year total shareholder return has declined 50.30%, indicating that recent momentum has picked up after a much tougher year for long term holders.

Capitalize on Everest Medicines’ CARDAMYST breakthrough by scanning our hand picked 618 high quality undiscovered gems, which combine strong fundamentals with under-the-radar potential.

Everest Medicines now trades well below both its own estimated intrinsic value and the average analyst target, even after the CARDAMYST news. Is that caution a useful warning sign or a misread on the risk reward?

Most Popular Narrative: 34% Undervalued

Compared with the last close at HK$27.98, the most followed narrative places Everest Medicines at a fair value of HK$42.18. This frames the recent CARDAMYST approval against a much bigger pipeline and licensing story.

The company's robust and diversified pipeline spanning mRNA vaccines, in vivo CAR-T, and novel autoimmune therapies with multiple assets moving toward late-stage trials positions Everest to benefit from global moves toward precision and targeted medicines, driving long-term revenue streams and earnings growth from innovative products.

See why 0 investors see Everest Medicines as 34% undervalued.

Result: Fair Value of HK$42.18 (UNDERVALUED)

Still, the bullish Everest Medicines story hinges on its heavy dependence on NEFECON and on securing pricing and reimbursement, which might prove tougher than analysts currently assume.

Find out about the key risks to this Everest Medicines narrative.

Next Steps

Mixed sentiment around Everest Medicines creates room for your own judgment, so move quickly through the available data and weigh the 4 key rewards and 1 important warning sign.

Hunting For More Everest Medicines Style Ideas?

If Everest Medicines has your attention, do not stop at a single ticker. Cast a wider net now so you are not chasing late moves later.

• Spot potential mispricings early and review our 198 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying business strength.
• Strengthen your income stream and scan the 165 dividend fortresses where payout potential meets balance sheet support for investors who care about steady cash returns.
• Prioritise resilience and stress test your watchlist against the 223 resilient stocks with low risk scores that focus on companies with calmer risk profiles and more defensive characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com